Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells

Rui Xu, Norihiro Sato, Kosuke Yanai, Takashi Akiyoshi, Shuntaro Nagai, Junji Wada, Kenichio Koga, Ryuichi Mibu, Masafumi Nakamura, Mitsuo Katano

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Resistance to chemotherapy represents a major obstacle to improving the survival of patients with colorectal cancer. In this study, the inhibition of the mitogen-activated protein kinase (MAPK) pathway was demonstrated to markedly enhance the apoptosis of colon cancer cells induced by paclitaxel, one of the key chemotherapeutic drugs widely used to treat various types of cancer. The treatment of the colon cancer cell lines SW480 and DLD-1 with paclitaxel resulted in increased activation of the MAPK pathway, which was blocked by PD98059, a MEK inhibitor. In both cell lines, MAPK inhibition by PD98059 led to a dramatic enhancement of the paclitaxel-induced apoptosis, as determined by cell cycle analysis and Hoechst 33342 staining, although the inhibitor alone did not affect apoptosis. This effect was restricted to paclitaxel since PD98059 did not alter the sensitivity to other drugs, including 5-fluorouracil (5-FU) and camptothecin (CPT). Importantly, selective blockage of the MAPK pathway by small interfering RNA (siRNA) also increased the apoptotic cell death induced by paclitaxel. These findings highlight the importance of the MAPK pathway in paclitaxel-induced apoptosis and suggest that a combined treatment with paclitaxel and MEK inhibitors could be an attractive therapeutic strategy against colon cancer.

Original languageEnglish
Pages (from-to)261-270
Number of pages10
JournalAnticancer research
Volume29
Issue number1
Publication statusPublished - Jan 1 2009

Fingerprint

Paclitaxel
Mitogen-Activated Protein Kinases
Colonic Neoplasms
Apoptosis
Mitogen-Activated Protein Kinase Kinases
Cell Line
Camptothecin
Fluorouracil
Pharmaceutical Preparations
Small Interfering RNA
Colorectal Neoplasms
Cell Cycle
Cell Death
Therapeutics
Staining and Labeling
Drug Therapy
Survival
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. / Xu, Rui; Sato, Norihiro; Yanai, Kosuke; Akiyoshi, Takashi; Nagai, Shuntaro; Wada, Junji; Koga, Kenichio; Mibu, Ryuichi; Nakamura, Masafumi; Katano, Mitsuo.

In: Anticancer research, Vol. 29, No. 1, 01.01.2009, p. 261-270.

Research output: Contribution to journalArticle

Xu, R, Sato, N, Yanai, K, Akiyoshi, T, Nagai, S, Wada, J, Koga, K, Mibu, R, Nakamura, M & Katano, M 2009, 'Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells', Anticancer research, vol. 29, no. 1, pp. 261-270.
Xu, Rui ; Sato, Norihiro ; Yanai, Kosuke ; Akiyoshi, Takashi ; Nagai, Shuntaro ; Wada, Junji ; Koga, Kenichio ; Mibu, Ryuichi ; Nakamura, Masafumi ; Katano, Mitsuo. / Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. In: Anticancer research. 2009 ; Vol. 29, No. 1. pp. 261-270.
@article{aff2cec73490454582ee8ca845a88019,
title = "Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells",
abstract = "Resistance to chemotherapy represents a major obstacle to improving the survival of patients with colorectal cancer. In this study, the inhibition of the mitogen-activated protein kinase (MAPK) pathway was demonstrated to markedly enhance the apoptosis of colon cancer cells induced by paclitaxel, one of the key chemotherapeutic drugs widely used to treat various types of cancer. The treatment of the colon cancer cell lines SW480 and DLD-1 with paclitaxel resulted in increased activation of the MAPK pathway, which was blocked by PD98059, a MEK inhibitor. In both cell lines, MAPK inhibition by PD98059 led to a dramatic enhancement of the paclitaxel-induced apoptosis, as determined by cell cycle analysis and Hoechst 33342 staining, although the inhibitor alone did not affect apoptosis. This effect was restricted to paclitaxel since PD98059 did not alter the sensitivity to other drugs, including 5-fluorouracil (5-FU) and camptothecin (CPT). Importantly, selective blockage of the MAPK pathway by small interfering RNA (siRNA) also increased the apoptotic cell death induced by paclitaxel. These findings highlight the importance of the MAPK pathway in paclitaxel-induced apoptosis and suggest that a combined treatment with paclitaxel and MEK inhibitors could be an attractive therapeutic strategy against colon cancer.",
author = "Rui Xu and Norihiro Sato and Kosuke Yanai and Takashi Akiyoshi and Shuntaro Nagai and Junji Wada and Kenichio Koga and Ryuichi Mibu and Masafumi Nakamura and Mitsuo Katano",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "29",
pages = "261--270",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells

AU - Xu, Rui

AU - Sato, Norihiro

AU - Yanai, Kosuke

AU - Akiyoshi, Takashi

AU - Nagai, Shuntaro

AU - Wada, Junji

AU - Koga, Kenichio

AU - Mibu, Ryuichi

AU - Nakamura, Masafumi

AU - Katano, Mitsuo

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Resistance to chemotherapy represents a major obstacle to improving the survival of patients with colorectal cancer. In this study, the inhibition of the mitogen-activated protein kinase (MAPK) pathway was demonstrated to markedly enhance the apoptosis of colon cancer cells induced by paclitaxel, one of the key chemotherapeutic drugs widely used to treat various types of cancer. The treatment of the colon cancer cell lines SW480 and DLD-1 with paclitaxel resulted in increased activation of the MAPK pathway, which was blocked by PD98059, a MEK inhibitor. In both cell lines, MAPK inhibition by PD98059 led to a dramatic enhancement of the paclitaxel-induced apoptosis, as determined by cell cycle analysis and Hoechst 33342 staining, although the inhibitor alone did not affect apoptosis. This effect was restricted to paclitaxel since PD98059 did not alter the sensitivity to other drugs, including 5-fluorouracil (5-FU) and camptothecin (CPT). Importantly, selective blockage of the MAPK pathway by small interfering RNA (siRNA) also increased the apoptotic cell death induced by paclitaxel. These findings highlight the importance of the MAPK pathway in paclitaxel-induced apoptosis and suggest that a combined treatment with paclitaxel and MEK inhibitors could be an attractive therapeutic strategy against colon cancer.

AB - Resistance to chemotherapy represents a major obstacle to improving the survival of patients with colorectal cancer. In this study, the inhibition of the mitogen-activated protein kinase (MAPK) pathway was demonstrated to markedly enhance the apoptosis of colon cancer cells induced by paclitaxel, one of the key chemotherapeutic drugs widely used to treat various types of cancer. The treatment of the colon cancer cell lines SW480 and DLD-1 with paclitaxel resulted in increased activation of the MAPK pathway, which was blocked by PD98059, a MEK inhibitor. In both cell lines, MAPK inhibition by PD98059 led to a dramatic enhancement of the paclitaxel-induced apoptosis, as determined by cell cycle analysis and Hoechst 33342 staining, although the inhibitor alone did not affect apoptosis. This effect was restricted to paclitaxel since PD98059 did not alter the sensitivity to other drugs, including 5-fluorouracil (5-FU) and camptothecin (CPT). Importantly, selective blockage of the MAPK pathway by small interfering RNA (siRNA) also increased the apoptotic cell death induced by paclitaxel. These findings highlight the importance of the MAPK pathway in paclitaxel-induced apoptosis and suggest that a combined treatment with paclitaxel and MEK inhibitors could be an attractive therapeutic strategy against colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=61449141236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449141236&partnerID=8YFLogxK

M3 - Article

C2 - 19331159

AN - SCOPUS:61449141236

VL - 29

SP - 261

EP - 270

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -